UNSPSC 51331604: Abaperidone

This classification denotes an antipsychotic agent with the molecular formula C25H25FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 40755Z8956, chemically known as 7-(3-(4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3-(hydroxymethyl)-4h-1-benzopyran-4-one but generally known as abaperidone, which bears US NIH Compound Identifier 3037308. Abaperidone most often appears in forms base and hydrochloride.

UNSPSC 51331604 Abaperidone is a Commodity code that in recent state and local procurement activity does not align with the pharmaceutical products actually being solicited. The three recent opportunities tagged to this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations concern abaperidone, an antipsychotic medication; the mismatch suggests either a data-tagging error in the source or that this code designation does not reflect actual procurement spend under the commodity. The recent activity shows state and local demand for pharmaceuticals, medical supplies, and pharmacy program administration, but not for the specific drug this code nominally represents.

Issuing bodies across recent records include a county health department (Seminole County), a state health commission (Texas HHS), and a multistate cooperative purchasing consortium (MMCAP, led by Minnesota). The Seminole County IFB (posted June 30, 2026, response due July 26, 2023) seeks annual procurement of naloxone and drug deactivation systems with quarterly deliveries. The Texas HHS RFI (posted April 3, 2026, response due April 3, 2026) explores vendor capacity for direct manufacturer contracting outside traditional pharmacy benefit manager channels. The MMCAP RFP (posted January 20, 2026, response due March 26, 2026) establishes statewide and multi-state contracts for generic pharmaceuticals and OTC products through authorized wholesalers, with evaluation weighted 75 percent on price competitiveness. Without confirmed abaperidone-specific demand in these records, the code shows limited decision-relevance for vendors focused on that commodity.